Brief: Lantern Pharma Receives Regulatory Approval To Expand Harmonic Clinical Trial For Non-Small Cell Lung Cancer
22/04/2024 13:52
April 22 (Reuters) - Lantern Pharma Inc LTRN.O :
* LANTERN PHARMA RECEIVES REGULATORY APPROVAL TO EXPAND
HARMONIC™
CLINICAL TRIAL FOR NON-SMALL CELL LUNG CANCER IN NEVER-SMOKERS
INTO JAPAN AND TAIWAN
Source text for Eikon: ID:nBw8nXL4Pa
Further company coverage: LTRN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lantern Pharma
See all newsBrief: Lantern Pharma Reports HARMONIC Data Showing LP-300 Progression-Free Survival Benefit Deepens With Treatment Duration In EGFR Exon 21 L858R Lung Cancer
Brief: Lantern Pharma Announces Successful Outcome Of FDA Type C Meeting Request For Harmonic Phase 2 Trial of LP-300 In Never-Smokers With NSCLC
Lantern Pharma Q1 net loss narrows on R&D cost cuts
Brief: Lantern Pharma Inc. Announces Up To $9.25 Million Registered Direct Offering With Existing Holders And A Single Institutional Investor
Brief: Lantern Pharma Inc - Schedules Type C FDA Meeting For Harmonic Protocol Amendments